IGSF21

Across TCGA pan-cancer cohorts, IGSF21 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated IGSF21 data layer compared with 21 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher IGSF21 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated IGSF21 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

GBM and LUAD are the cancer types where IGSF21 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.776	0.663	.021	2	view →
LUAD	DFS	Quartile	All	0.549	1.000	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

IGSF21–GBM (DFS)

Open the GBM breakdown →